Extrahepatic manifestations of chronic hepatitis C infection: a consecutive study in Brazilian patients

Tengan, Fátima Mitiko; Levy‐Neto, Maurício; Miziara, Ivan Dieb; Dantas, Bianca Peixoto; Maragno, Luciana

doi:10.1016/j.bjid.2016.09.018

Cited by 5 publications

(12 citation statements)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results concerning the economic burden associated with CHC were consistent with recent evidence from the US [ 20 ]. However, in contrast to previous results [ 19 , 21 ], the prevalence of cardiovascular disease was significantly higher in the cohort without CHC than the CHC cohort. This also contrasts the difference in economic burden attributed to cardiovascular EHCs observed in the present study, where the CHC cohort incurs a greater cost (Table 5 ).…”

Section: Discussioncontrasting

confidence: 99%

“…* Diabetes mellitus, type 2 [ 11 ] E14. * Diabetes mellitus, not further specified [ 21 ] Cardiovascular disease I20.*-I25. * Ischemic heart diseases [ 11 ] I60.*-I69.…”

Section: Methodsmentioning

confidence: 99%

“…* Chronic kidney disease [ 22 ] N19. * Renal failure, not further specified [ 11 ] D89.1 Cryoglobulinemia [ 21 , 24 ] Malignancies C85. * Other and not further specified types of Non-Hodgkin-lymphoma [ 20 ] Behavioral factors Mental and behavioral disorders (due to opiods, or multiple and other psychoactive substances) F11.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

et al. 2018

View full text Add to dashboard Cite

IntroductionGerman data regarding the burden of complications from chronic hepatitis C (CHC) virus infection are limited. To address this issue, this study evaluates the clinical and economic burden of hepatic and extrahepatic complications (EHCs) associated with CHC in Germany.MethodsThis retrospective, cross-sectional study used claims data from the Betriebskrankenkasse German sickness fund (2007–2014) to assess the risks and medical costs of hepatic complications and EHCs, including conditions that are prevalent and behavioral factors associated with CHC. Prevalence, incidence, and risks were calculated for 1:1 matched patients with and without CHC (n = 3994). All-cause cost, medical costs related to hepatic and EHCs, as well as CHC-related and non-CHC-related pharmacy costs (adjusted to the 2016 Euro rate), were calculated and compared between 1:5 matched patients with (n = 8425) and without CHC (n = 42,125).ResultsPatients with CHC had a 3-fold higher risk for any EHC (OR = 3.0; P < 0.05) and higher EHC-related medical costs (adjusted difference, €1606; P < 0.01) compared with patients without CHC. Total costs (€10,108 vs. €5430), hepatic complication-related medical costs (€1425 vs. €556), EHC-related costs (€3547 vs. €1921), CHC-related pharmacy costs (€577 vs. €116), and non-CHC-related pharmacy costs (€3719 vs. €1479) were all significantly greater for patients with CHC compared with patients without CHC. EHC-related medical costs were a major contributor to the higher all-cause medical (84.4%) and total (44.3%) cost differences between patients with CHC and the matched sample of patients without CHC.ConclusionCHC is associated with substantial clinical and economic burden in Germany, largely due to hepatic complications and EHCs.FundingAbbvie Inc.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…* Diabetes mellitus, type 2 [ 11 ] E14. * Diabetes mellitus, not further specified [ 21 ] Cardiovascular disease I20.*-I25. * Ischemic heart diseases [ 11 ] I60.*-I69.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

et al. 2018

View full text Add to dashboard Cite

show abstract

“…* Diabetes mellitus, type 2 [ 9 ] E14. * Diabetes mellitus, not further specified [ 30 ] Cardiovascular disease I20.*–I25. * Ischemic heart diseases [ 9 ] I60.*–I69.…”

Section: Methodsmentioning

confidence: 99%

“…* Chronic kidney disease [ 15 ] N19. * Renal failure, not further specified [ 9 ] D89.1 Cryoglobulinemia [ 30 , 32 ] Malignancies C85. * Other and not further specified types of Non-Hodgkin-lymphoma [ 22 ] Behavioral factors Mental and behavioral disorders (due to opiods or multiple and other psychoactive substances) F11.…”

Section: Methodsmentioning

confidence: 99%

Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

et al. 2018

View full text Add to dashboard Cite

IntroductionGerman data regarding the economic burden of chronic hepatitis C (CHC) and potential benefits of CHC treatment are limited. To address this issue, we evaluated the role of treatment in mitigating the economic burden of hepatic and extrahepatic complications (EHCs) from CHC virus infection in Germany.MethodsThis retrospective, cross-sectional study used claims data from the Betriebskrankenkasse German sickness fund (2007–2014) to assess the medical costs of hepatic complications and EHCs, including conditions that are prevalent and behavioral factors associated with CHC. All-cause costs, medical costs related to hepatic and EHCs, and CHC-related and non-CHC-related pharmacy costs (adjusted to the 2016 euro rate) were calculated and compared between CHC patients’ treated (n = 1714) and untreated time (n = 7124) and CHC patients that initiated treatment early (i.e., without cirrhosis; n = 1552) vs. late (i.e., with cirrhosis; n = 162).ResultsCHC treatment was associated with an average adjusted savings of €1885 in annual all-cause medical costs per patient, with a significant proportion attributed to EHC-related cost savings (adjusted difference, €1363; P < 0.01). Although initiating CHC treatment early was economically beneficial compared with initiating treatment late, the total cost savings were not significantly different (annual average adjusted difference, €3831; P = 0.27). However, nearly 60% of these savings were EHC related (adjusted difference, €2255; P < 0.01).ConclusionCHC is associated with a significant economic burden in Germany, largely due to EHCs. Antiviral treatment may reduce the burden of CHC and result in significant cost savings, even when initiated at earlier stages of liver disease.FundingAbbVie Inc.

show abstract

Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients

Aguiar

Faria-Janes

Garcia-Brandes

et al. 2019

Annals of Hepatology

View full text Add to dashboard Cite

Extrahepatic manifestations of chronic hepatitis C infection: a consecutive study in Brazilian patients

Cited by 5 publications

References 6 publications

Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data

Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data

Prevalence of cryoglobulinemia and cryoglobulinemic vasculitis in chronically HCV-infected Brazilian patients

Contact Info

Product

Resources

About